Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2014

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gdn55
    wrote on sidst redigeret af
    #659

    Hvad mon der sker efter luk.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #660

      Det rykker noget i dag...

      1 Reply Last reply
      0
      • investor1989I Offline
        investor1989I Offline
        investor1989
        wrote on sidst redigeret af
        #661

        +6% er længe siden vi sidst har set

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #662

          +4% på c20 indeks ?

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #663

            Er væksten kommet til Europa ?

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JKY_VH
              wrote on sidst redigeret af
              #664

              Det er bare mig der er kommet hjem fra ferie:-)

              1 Reply Last reply
              0
              • C Offline
                C Offline
                cpi
                wrote on sidst redigeret af
                #665

                tja, det luk i us bliver vi vist ikke klogere af, hælder mest til, vi skal ned på mandag, måske en 3-5 kr.

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #666

                  Jeg synes den er helt umulig at spå om...

                  1 Reply Last reply
                  0
                  • investor1989I Offline
                    investor1989I Offline
                    investor1989
                    wrote on sidst redigeret af
                    #667

                    Revlimid det 10 dyreste lægemiddel pr. patient i verden: http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013 Alexions lægemiddel klart dyrest

                    1 Reply Last reply
                    0
                    • BudweisB Offline
                      BudweisB Offline
                      Budweis
                      wrote on sidst redigeret af
                      #668

                      Dette interview William R. Strohl (VP hos Janssen) er ret interessant - http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/why-the-next-big-biologic-may-be-found-by-montco.h
                      tml

                      1 Reply Last reply
                      0
                      • BudweisB Offline
                        BudweisB Offline
                        Budweis
                        wrote on sidst redigeret af
                        #669

                        Just a moment...

                        favicon

                        (www.bizjournals.com)

                        1 Reply Last reply
                        0
                        • BudweisB Offline
                          BudweisB Offline
                          Budweis
                          wrote on sidst redigeret af
                          #670

                          Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”

                          Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #671

                            Tak for info Budweis.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #672

                              Ja meget opmuntrende læsning. Kunne Janssen så ikke lige også nappe en aftale på hexabody.

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #673

                                Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #674

                                  Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #675

                                    OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen

                                    1 Reply Last reply
                                    0
                                    • investor1989I Offline
                                      investor1989I Offline
                                      investor1989
                                      wrote on sidst redigeret af
                                      #676

                                      Genmab vil have adgang til flere antistoffer som de kan kombinere i duobody

                                      1 Reply Last reply
                                      0
                                      • celsiusC Offline
                                        celsiusC Offline
                                        celsius
                                        wrote on sidst redigeret af
                                        #677

                                        Det Europæiske Lægemiddelagentur har godkendt lægemidlet Imbruvica (ibrutinib) fra Janssen og partneren Pharmacyclics til to indikationer inden for behandling af blodkræft. Markedet skærpes nu for alvor for Genmab. Er der nogen der ønsker at kommentere på det ? I artiklen står der at Imbrutinib skulle være i fase 3 kombi med Arzerra .. har det sin rigtighed ?

                                        1 Reply Last reply
                                        0
                                        • celsiusC Offline
                                          celsiusC Offline
                                          celsius
                                          wrote on sidst redigeret af
                                          #678

                                          Citat MedWatch i dag: ”Det store Genmab-håb er, at man succesfuldt kan kombinere Arzerra med Imbruvica. I øjeblikket er den kombinationsbehandling i fase 3, efter selvsamme kombination tidligere har vist særdeles stærke data i et mindre fase 2-studie”

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger